» Articles » PMID: 37860622

Machine Learning Approach to Evaluate TdP Risk of Drugs Using Cardiac Electrophysiological Model Including Inter-individual Variability

Overview
Journal Front Physiol
Date 2023 Oct 20
PMID 37860622
Authors
Affiliations
Soon will be listed here.
Abstract

Predicting ventricular arrhythmia Torsade de Pointes (TdP) caused by drug-induced cardiotoxicity is essential in drug development. Several studies used single biomarkers such as qNet and Repolarization Abnormality (RA) in a single cardiac cell model to evaluate TdP risk. However, a single biomarker may not encompass the full range of factors contributing to TdP risk, leading to divergent TdP risk prediction outcomes, mainly when evaluated using unseen data. We addressed this issue by utilizing multi- features from a population of human ventricular cell models that could capture a representation of the underlying mechanisms contributing to TdP risk to provide a more reliable assessment of drug-induced cardiotoxicity. We generated a virtual population of human ventricular cell models using a modified O'Hara-Rudy model, allowing inter-individual variation. and Hill coefficients from 67 drugs were used as input to simulate drug effects on cardiac cells. Fourteen features (, , , , , , , , , , , , qNet, qInward) could be generated from the simulation and used as input to several machine learning models, including k-nearest neighbor (KNN), Random Forest (RF), XGBoost, and Artificial Neural Networks (ANN). Optimization of the machine learning model was performed using a grid search to select the best parameter of the proposed model. We applied five-fold cross-validation while training the model with 42 drugs and evaluated the model's performance with test data from 25 drugs. The proposed ANN model showed the highest performance in predicting the TdP risk of drugs by providing an accuracy of 0.923 (0.908-0.937), sensitivity of 0.926 (0.909-0.942), specificity of 0.921 (0.906-0.935), and AUC score of 0.964 (0.954-0.975). According to the performance results, combining the electrophysiological model including inter-individual variation and optimization of machine learning showed good generalization ability when evaluated using the unseen dataset and produced a reliable drug-induced TdP risk prediction system.

Citing Articles

Cardiotoxicity evaluation of two-drug fixed-dose combination therapy under CiPA: a computational study.

Qauli A, Marcellinus A, Vanheusden F, Lim K Transl Clin Pharmacol. 2025; 32(4):198-215.

PMID: 39801776 PMC: 11711388. DOI: 10.12793/tcp.2024.32.e20.


QSAR Classification Modeling Using Machine Learning with a Consensus-Based Approach for Multivariate Chemical Hazard End Points.

Fuadah Y, Pramudito M, Firdaus L, Vanheusden F, Lim K ACS Omega. 2025; 9(51):50796-50808.

PMID: 39741811 PMC: 11683616. DOI: 10.1021/acsomega.4c09356.


A stacking ensemble machine learning model for evaluating cardiac toxicity of drugs based on in silico biomarkers.

Fuadah Y, Qauli A, Pramudito M, Marcellinus A, Hanum U, Lim K CPT Pharmacometrics Syst Pharmacol. 2024; 13(12):2159-2170.

PMID: 39185761 PMC: 11646942. DOI: 10.1002/psp4.13229.

References
1.
Crumb Jr W, Vicente J, Johannesen L, Strauss D . An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J Pharmacol Toxicol Methods. 2016; 81:251-62. DOI: 10.1016/j.vascn.2016.03.009. View

2.
Mirams G, Cui Y, Sher A, Fink M, Cooper J, Heath B . Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res. 2011; 91(1):53-61. PMC: 3112019. DOI: 10.1093/cvr/cvr044. View

3.
Montomoli J, Romeo L, Moccia S, Bernardini M, Migliorelli L, Berardini D . Machine learning using the extreme gradient boosting (XGBoost) algorithm predicts 5-day delta of SOFA score at ICU admission in COVID-19 patients. J Intensive Med. 2023; 1(2):110-116. PMC: 8531027. DOI: 10.1016/j.jointm.2021.09.002. View

4.
Parikh J, Gurev V, Rice J . Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features. Front Pharmacol. 2017; 8:816. PMC: 5694470. DOI: 10.3389/fphar.2017.00816. View

5.
Tomek J, Bueno-Orovio A, Passini E, Zhou X, Minchole A, Britton O . Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block. Elife. 2019; 8. PMC: 6970534. DOI: 10.7554/eLife.48890. View